With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.

The company’s AN9025 will shortly enter phase 1.

Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.

A more comprehensive dataset on JANX007 sends the group’s stock down.

But the group still hopes to get IGV-001 approved based on overall survival data.

The agency approved eight oncology products over the month.